What Outcomes Should I Track for Self-Injury if Trying Any New Treatment?

Self-injury, often defined as deliberate harm to oneself without suicidal intent, is a complex behavior frequently seen among autistic individuals but also associated with a range of co-occurring conditions such as epilepsy or mental health disorders. When trying any new treatment aimed at reducing self-injurious behavior (SIB), it’s essential to track specific outcomes carefully to assess benefits and harms objectively and ensure the approach aligns with professional guidelines.

In this post, I’ll walk you through the key outcomes you should monitor, emphasize the importance of distinguishing autism itself from related conditions, review what the National Institute for Health and Care Excellence (NICE) and General Medical Council (GMC) recommend, and discuss the limitations of current treatments including the role of placebo effects.

Understanding Self-Injury and Its Context

Before listing outcomes, let’s briefly define the core symptom being treated—self-injury.

What is self-injury?

Self-injury refers to acts of harming one’s body tissue, such as cutting, scratching, head-banging, or biting oneself. Importantly, it’s distinct from suicidal behavior as it generally does not aim to cause death. Among autistic individuals, self-injury can serve various functions, including sensory regulation, communication of distress, or response to pain from other conditions.

Autism vs. co-occurring conditions

If you’re trying treatments, clarity about whether the self-injury is primarily linked to autism or associated medical or psychiatric conditions is crucial. For example:

• Epilepsy: Certain types of epilepsy may increase risk of self-injury during seizures or postictal confusion.
• Mental Health Disorders: Anxiety, depression, or trauma-related disorders can have overlapping behaviors.
• Gastrointestinal or sensory issues: Chronic pain or discomfort can fuel self-harming behaviors.

Tracking outcomes separately for autism-related and co-occurring conditions helps avoid conflating effects and informs appropriate treatment adjustments.

What Does NICE Recommend (and What It Does NOT)?

The National Institute for Health and Care Excellence (NICE) is the UK’s authoritative body for evidence-based healthcare guidance. Their recommendations carry significant weight for clinicians and families alike.

Key NICE guidance on self-injury

• NICE guidance emphasizes behavioral and psychosocial interventions as first-line approaches.
• Pharmacological treatments are recommended only for specific co-occurring conditions or if non-drug treatments have failed, and even then require careful monitoring.
• Self-injury as a behavior is not itself listed as an indication for “treatment” with cannabis-derived products or other off-label medications.

You can find this guidance in detail through the NICE guidance library.

What NICE does not recommend

It is important to note what NICE does not support:

• No current NICE guidance endorses the use of cannabis-based products specifically for self-injury in autism outside of tightly defined epilepsy syndromes.
• Claims of “calming” or “improved behavior” without reproducible, objective evidence do not meet NICE’s standards for recommending treatments.
• Treatments offered without clear measurement plans tracking incident frequency and risk are discouraged.

Role of the General Medical Council (GMC)

The GMC provides standards for doctors in the UK, emphasizing that prescribing medicines outside of licensed indications requires a robust evidence base and informed consent. This means any off-label use must be justified with clear outcome tracking and safety monitoring.

Focus Keywords: What Outcomes to Track

When testing any new treatment for self-injury, londoninsider.co.uk these are the three fundamental outcome domains you should monitor and document carefully:

1. Incident Frequency
2. Severity Notes
3. Risk of Harm

1. Incident Frequency

Track how often self-injury occurs during defined time periods (daily, weekly). Document:

• Number of episodes per day or week
• Duration of episodes (if applicable)
• Triggers or contexts in which incidents most frequently occur

This provides a baseline and lets you detect increases, decreases, or trends over time.

2. Severity Notes

Not all self-injury is equally severe. Consider documenting:

• Type of injury (e.g., superficial scratching vs. deep cuts)
• Body areas affected, especially high-risk sites (head, neck)
• Need for medical intervention (bandaging, stitches, etc.)
• Pain level or physical consequences

Keeping a simple severity scale (e.g., mild, moderate, severe) can aid consistency.

3. Risk of Harm

Assess whether the self-injury poses imminent or serious risk, including:

• Potential or actual tissue damage requiring urgent care
• Signs of infection or other complications
• Emergence of suicidal ideation or intent (separate from non-suicidal self-injury)

Risk assessment must be ongoing, especially if new treatments might alter behavior unpredictably.

Additional Outcomes to Consider

Depending on the individual and treatment, the following may also be important to monitor:

• Quality of life measures: Sleep, mood, engagement in daily activities
• Side effects: Any unwanted drug or therapy effects
• Co-occurring symptoms: Anxiety, seizures, or aggression if present

Understanding Narrow Epilepsy Indications for Certain Treatments

When it comes to cannabis-based medicinal products (CBMPs), NICE only recognizes specific epilepsy syndromes— Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex—as licensed indications. This means their use for self-injurious behavior outside these contexts lacks strong regulatory or clinical endorsement.

Families and clinicians should be cautious about claims of benefit for autism-related self-injury not linked to these epilepsy types. NHS England’s policy and NICE technology appraisals make these distinctions clear to prevent misuse or false expectations.

Limitations of Available Evidence and the Placebo Effect

Current research into treatments for self-injury in autism and related conditions is quite limited. Many studies:

• Have small sample sizes
• Use non-standardized outcome measures
• Are open-label or unblinded, increasing risk of placebo and observer bias

The placebo effect—where perceived improvement results from expectation rather than the treatment itself—is a well-documented challenge. It underscores the importance of careful, objective tracking rather than relying on subjective impressions alone.

Checklist: Before Starting a New Treatment for Self-Injury

• Ensure a clear diagnosis separating autism from any co-occurring conditions
• Review NICE guidance and confirm treatment aligns or is justified off-label with informed consent
• Establish a baseline for incident frequency, severity, and risk of harm
• Agree on a measurable and repeatable way to log outcomes
• Plan regular reviews with healthcare providers
• Be alert for side effects or emerging risks

Summary

Tackling self-injury requires a nuanced, evidence-based approach. By focusing on core outcomes—incident frequency, severity notes, and risk of harm—you can objectively evaluate any new treatment’s impact. Always consult NICE guidelines and the GMC’s principles for safe prescribing, recognizing that autism-related self-injury may overlap with co-occurring conditions requiring distinct management.

With careful tracking and professional guidance, families and clinicians can make informed decisions, avoid unproven claims, and prioritize safety and well-being.

For more information, visit the NICE guidance library and GMC official site.